Genetics and Business

I have been busy lately but found some time to go through an interesting story and a good article published in scientist magazine

  1. Father-in-law of now-infamous extensively drug-resistant TB patient studies tuberculosis at the CDC, and is now under review by the agency
  2. Genotyping with PCR -How to choose the right approach

I am working on an article about consolidation in Microarray and Bioinformatics industry so interesting to know about GenoLogics Announces Bioinformatics Partnership with Illumina  so is the  news of Roche acquiring Nimblgen and the end of patent wars with Affymetrix, Roche has also acquired 454 life sciences, It seems Roche plans to get inot clinical genomcis and theranostics application industry, the company already has FDA approved amplichip CYP450 arrays for clinical diagnostics

With many other acquisitions in the last one year  and many more in the pipeline it seems paydays for early starters.

12 DNA tests that Could Change Your Life-selected by Forbes

The complete list is published at forbes website

  • Breast Cancer
  • Adult-Onset Diabetes
  • Obesity
  • Drug Metabolism
  • Crohn’s Disease
  • Prostate Cancer
  • Duchenne Muscular Dystrophy
  • Rett Syndrome
  • Macular Degeneration
  • Alzheimer’s Disease
  • Heart Attack

Gene Testing:

Related Blogs

eyeondna , gensherpa , OmicsOmics

Microarray based DRUG DISCOVERY and CLINICAL DIAGNOSIS and biosensor designed to identify viruses

 Prof. David Dandy of Colorado State University chemical and biological engineering has proven that called microarray assays can be used for biomedical disease and drug screening assays could rapidly increase drug discovery,

Although not ready for hospital or office use, microarrays represent a novel miniaturized multi-spot diagnostic format that has huge potential for patient diagnosis if found reliable and approved.

Smaller is often better, according to a new scientific study that appears this week in the Proceedings of the National Academy of Sciences by Professor David Dandy, Dr. David Dandyhead of the Department of Chemical and Biological Engineering at Colorado State. Dandy co-wrote the paper with David Grainger, a former chemistry professor at Colorado State who now is chair of the Department of Pharmaceutics & Pharmaceutical Chemistry at the University of Utah.

The study was funded by a multi-year, $2.5 million grant from the National Institutes of Health.

“This work is extremely useful from an industrial perspective,” said Michael Lochhead, chief scientist at Accelr8 Technology Corp., a Denver-based developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection.

The critical importance of this work is illustrated by the fact that, to date, a single microarray-based test has been approved by the FDA for clinical use.

According to Roche, the manufacturer of this diagnostic microarray, “This test analyzes a patient’s Cytochrome P450 2D6 and 2C19 genotypes from genomic DNA extracted from a blood sample. Test results will allow physicians to consider unique genetic information from patients in selecting medications and doses of medications for a wide variety of common conditions such as cardiac diseases, pain and cancer.”

 

 

%d bloggers like this: